May 24, 2024 DCVMN Teamed Up with Leading Vaccine Experts and Manufacturers to Co-author an Article on the Pandemic Agreement Article CEO DCVMN Advocacy DCVMNpartnerships Pandemic Preparedness
May 23, 2024 The Pandemic Agreement: A Bridge to Nowhere or North Star to Access and Global Health Security? COVID-19 developingcountries GlobalHelath
May 8, 2024 DCVMN Board at the 8th International Symposium on Immunobiologicals in Rio de Janeiro Brazil DCVMN Board developingcountries Vaccines & immunization WeConnectToProtect
April 25, 2024 DCVMN CEO Inaugurating the Vaccine World Forum in Pune CEO developingcountries Vaccines & immunization WeConnectToProtect
April 11, 2024 DCVMN Board at the World Vaccine Congress DCVMN Advocacy DCVMN Board developingcountries Vaccines & immunization
April 10, 2024 DCVMN at the World Vaccine Congress Biodefence Pre-Workshop CEO DCVMN Advocacy Pandemic Preparedness Vaccines & immunization
April 3, 2024 DCVMN CEO Engagements in Addis Ababa Africa CEO DCVMN Advocacy developingcountries WeConnectToProtect
March 31, 2024 DCVMN CEO at the International Conference on Innovation, Intellectual Property, and Technology Transfer in Africa’s Pharmaceutical Sector CEO Conference DCVMN Advocacy
March 18, 2024 DCVMN Chairing “Facilitating Technology Transfer to Promote Local Manufacturing and Access to Vaccines, Medicines, and Health Technologies in Sub-Saharan Africa” Conference CEO Conference DCVMN Advocacy
March 14, 2024 DCVMN Joint Statement with IFPMA and Trade Associations on Biopharmaceutical Industry Commitments DCVMN Advocacy developingcountries Statement WeConnectToProtect
December 15, 2023 Panacea Biotec launches EasyFourPol® in India and receives registration of Valganciclovir Powder for Oral Solution in Germany Global Health Healthcare Milestones Vaccine Equity Vaccines & immunization Vacine Innovation WeConnectToProtect
